Cannara Biotech (CNSX:LOVE – Free Report) had its price objective raised by TD from $3.25 to $4.00 in a research report report published on Thursday morning,BayStreet.CA reports. The firm currently has a buy rating on the stock.
Separately, Haywood Securities set a $3.00 price target on shares of Cannara Biotech and gave the company a “buy” rating in a research report on Monday, April 6th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $3.42.
View Our Latest Research Report on LOVE
Cannara Biotech Price Performance
Cannara Biotech Company Profile
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
See Also
- Five stocks we like better than Cannara Biotech
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
